Experience

Pleco Therapeutics BV

• Netherlands
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Chief Business Officer - Chairman of the non-Executive Board and co-Founder at Pleco Therapeutics BV

  • 2018 - 5 years

  Nijmegen, Gelderland, Netherlands Pleco Therapeutics BV is a Dutch private limited company, established to develop a portfolio of therapies in the field of cancer medicine. Pleco utilises a global network of academic centres and contract research organisations to test highly-efficient Fixed-Dose Combinations, repurposing existing therapies. The first Fixed-Dose Combination is currently being tested in clinical models.



Obvius Pharmaceuticals B.V

• Director Of Business Development

  • Feb 2014 - Dec 2020

  Amsterdam Area The Netherlands



IDIS Pharmaceuticals

• Director Commercial Development

  • Nov 2013 - Jun 2015

  United Kingdom

• Director International Sales

  • Mar 2010 - Nov 2013

  Around the world, many patients with serious illnesses are unable to access the medicines they need. These patients may have exhausted all available commercial therapies for their disease, they may not be able to participate in a clinical trial, or they may live in a country where a much needed medicine will not be made available through commercial routes. Idis is the leading expert in helping patients gain access to much needed medicines when the traditional routes to access aren’t available… Show more Around the world, many patients with serious illnesses are unable to access the medicines they need. These patients may have exhausted all available commercial therapies for their disease, they may not be able to participate in a clinical trial, or they may live in a country where a much needed medicine will not be made available through commercial routes. Idis is the leading expert in helping patients gain access to much needed medicines when the traditional routes to access aren’t available or aren’t fast enough. For the past 25 years Idis has partnered with pharmaceutical and biotechnology companies and healthcare providers to create regulatory-compliant, ethical access for patients with unmet medical needs. My main responsabilities/achievements: Setting up Global Partner Programmes - Global Busines Development- Setting up French Pharmaceutical Subsidiary-Growing International Sales >50%



Care4Pharma

• Medical Practices

• Advisor to the Board

  • Mar 2011 - 2012

  Switzerland



Jansen Pharma sprl

• Founder & Managing Director

  • Apr 1996 - Dec 2010

  JP Holding SPRL is a management and consulting company with over 30 years of experience in the pharmaceutical industry. We provide management consulting services, specializing in the areas of European Union (including Eastern Europe) market entry, business development, licensing, project management and merger and acquisition support including fundraising for small to medium size pharmaceutical companies to help them to grow their business.



Strides Arcolab Limited

• CEO Europe

  • Aug 2008 - Jun 2010

  Cyprus

• CEO Europe

  • Sep 2008 - Mar 2010

  Strides Europe includes the following entities in Europe: Manufacturing at Beltapharm in Italy - Milano (semi-solids) and Strides Poland in Warsaw (vials, ampoules and PFS). Sales/Marketing in the UK through fully owned subsidiaries:UK: Copharm, Scandinavia: Farma+, Spain/Portugal: Domac. In April 2009 Strides has opened an office in Belgrade, Serbia.



Intsel-Chimos

• France
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Managing Director

  • 2004 - 2008

  Specialty Pharmaceutical Business located in Paris, France.


Wockhardt Ltd.
• India
• Pharmaceutical Manufacturing
• 700 & Above Employee
• President

  • 1996 - 1998


The Upjohn Company

• Insurance
• 1 - 100 Employee

• Director

  • Oct 1976 - Jun 1996

  Netherlands, Belgium, USA and Czech Republic



Upjohn

• United Kingdom
• 1 - 100 Employee

• Regional Marketing Director

  • 1989 - 1996

  Developing Regional Marketing Strategies - Implement shared marketing programmes in EER- Liaison between US HQ and EER - Implementing Marketing training programmes- Driver to increase turnover by > 10% to 80 million USD